Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer

Juliana Lenzi; Andre Deeke Sasse

doi:10.1055/s-0045-1807969

Brazilian Journal of Oncology, Inhaltsverzeichnis

CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1807969

PUBLIC POLICY, ACCESS, PHARMACOECONOMICS AND HEALTH MANAGEMENT

1950

POSTER PRESENTATION

Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer

Autoren

Juliana Lenzi
Andre Deeke Sasse

Abstract

Alle Artikel dieser Rubrik

Keywords

cost-effectiveness analysis - Metastatic breast cancer - CDK4/6 inhibitors - healthcare economics - price negotiations

Bibliographical Record
Juliana Lenzi, Andre Deeke Sasse. Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer. Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1807969

Volltext